MedTrace Logo

Interaction of Sevoflurane Propofol and Remifentanil in Anesthesia for Laparoscopic Surgery

NCT02457442 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2023-11-29

No results posted yet for this study

Summary

Recently a new model for the interaction of sevoflurane propofol and remifentanil was developed. The potency of any combination of the three drugs is defined as probability that a subject tolerates laryngoscopy without movement response. The model allows to compare the potency of intravenous and inhalation anesthetics. If the model is valid also for other stimuli than laryngoscopy and for other responses (e.g. blood pressure or heart rate increase upon stimulation). If the model is valid equipotent concentrations of sevoflurane and propofol the same remifentanil concentration would be sufficient to suppress hemodynamic response to a given stimulus. This will be investigated it the study.

Conditions

  • Drug Interactions
  • Anesthesia, Conduction

Interventions

DRUG

Propofol and Remifentanil

High propofol and low remifentanil, changing remifentanil (up-and-down method)

DRUG

Propofol and Remifentanil

Low propofol and high remifentanil, changing propofol (up-and-down method)

DRUG

Sevoflurane and Remifentanil

High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)

DRUG

Sevoflurane and Remifentanil

Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)

DRUG

SPR 1

Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil. SPR 1: Changing Propofol for skin incision.

DRUG

SPR2

Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil. Changing Sevoflurane for skin incision.

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Martin Luginbühl, PD Dr. med. · Spital Tiefenau, Inselgruppe, Abteilung für Anästhesie und Intensivmedizin

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2023-10-23
Completion
2023-10-23

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02457442 on ClinicalTrials.gov